Patents by Inventor John C. Kappes
John C. Kappes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11560413Abstract: The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, S495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, S1255L, K1334G, S1359A, E1371Q, H1402S, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.Type: GrantFiled: February 15, 2019Date of Patent: January 24, 2023Assignees: UAB Research Foundation, Texas Tech University SystemInventors: John C. Kappes, Zhengrong Yang, Christie G. Brouillette, Ina L. Urbatsch
-
Publication number: 20190248855Abstract: The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, 5495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, 51255L, K1334G, 51359A, E1371Q, H14025, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.Type: ApplicationFiled: February 15, 2019Publication date: August 15, 2019Inventors: John C. Kappes, Zhengrong Yang, Christie G. Brouillette, Ina L. Urbatsch
-
Publication number: 20160145641Abstract: A method useful for making a eukaryotic membrane protein in vitro may be carried out by (a) propagating in vitro vertebrate stem cells; (b) transforming the vertebrate stem cells in vitro with a heterologous expression vector containing a nucleic acid encoding the eukaryotic membrane protein; and then (c) differentiating the stem cells in vitro into differentiated cells (or photoreceptor-like cells) that express the membrane protein.Type: ApplicationFiled: March 26, 2014Publication date: May 26, 2016Inventors: Lawrence J. DELUCAS, John C. KAPPES
-
Publication number: 20110229964Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: ApplicationFiled: February 25, 2011Publication date: September 22, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20110004951Abstract: This invention relates to methods and compositions for identifying compounds that inhibit HIV-1 subunit-specific reverse transcriptase.Type: ApplicationFiled: May 24, 2005Publication date: January 6, 2011Inventors: John C. Kappes, Alok Mulky, Xiaoyun Wu
-
Patent number: 7622300Abstract: Trans-lentiviral gene transfer vectors, vector systems, vector particles, and methods for transduction of primary nondividing cells using the same, are described. Further described are modifications to the gene transfer vectors that improve transduction efficiency and/or gene expression, e.g., by incorporating the cis-acting sequences, PPT-CTS and/or WPRE, and derivatives or analogs thereof.Type: GrantFiled: July 24, 2002Date of Patent: November 24, 2009Inventors: John C. Kappes, Xiaoyun Wu
-
Patent number: 7534603Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: GrantFiled: October 15, 2002Date of Patent: May 19, 2009Assignee: The UAB Research FoundationInventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20080233639Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: ApplicationFiled: August 20, 2007Publication date: September 25, 2008Inventors: John C. Kappes, Xiaoyun Wu
-
Patent number: 7259014Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: GrantFiled: September 17, 2002Date of Patent: August 21, 2007Assignee: UAB Research FoundationInventors: John C. Kappes, Xiaoyun Wu
-
Patent number: 6797462Abstract: Methods and reagents for the capture of primary HIV are provided. A cell line expressing CCR5, CXCR4 and CD4 receptors binds and is infected by primary HIV. The cell line contains a marker gene sequence, the marker gene sequence expressed in near linear quantities over at least two orders of magnitude in response to HIV infection. Primary HIV is amplified to create a primary virus stock through insertion of an amplicon gene into the receptor expressing cell line. HIV amplification occurs rapidly and is operative with noninfectious HIV through amplification in the presence of an infectivity complement. The present invention is useful in determining host HIV titer, drug sensitivity, HIV amplification, gene sequencing and co-receptor utilization.Type: GrantFiled: April 13, 2001Date of Patent: September 28, 2004Assignee: UAB Research FoundationInventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20040010135Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: ApplicationFiled: October 15, 2002Publication date: January 15, 2004Inventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20030166563Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: ApplicationFiled: March 20, 2003Publication date: September 4, 2003Applicant: University of Alabama Research FoundationInventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20030157690Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: ApplicationFiled: November 27, 2002Publication date: August 21, 2003Applicant: UAB Research FoundationInventors: John C. Kappes, Xiaoyun Wu
-
Patent number: 6555342Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: GrantFiled: December 14, 1999Date of Patent: April 29, 2003Assignee: UAB Research FoundationInventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20030072938Abstract: Trans-lentiviral gene transfer vectors, vector systems, vector particles, and methods for transduction of primary nondividing cells using the same, are described. Further described are modifications to the gene transfer vectors that improve transduction efficiency and/or gene expression, e.g., by incorporating the cis-acting sequences, PPT-CTS and/or WPRE, and derivatives or analogs thereof.Type: ApplicationFiled: July 24, 2002Publication date: April 17, 2003Inventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20020173643Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: ApplicationFiled: December 5, 2000Publication date: November 21, 2002Inventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20020151710Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: ApplicationFiled: March 7, 2002Publication date: October 17, 2002Inventors: John C. Kappes, Xiaoyun Wu